Drospirenone/ethinyl estradiol.

Drospirenone/ethinyl estradiol. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Drospirenone/ethinyl estradiol. Abstract Text:

Andrea J Rapkin,Shelley N Sorger,Sharon A Winer,

Drospirenone 3 mg/ethinyl estradiol 20 microg (24/4) is a new unique oral contraceptive formulation that combines in a novel dosing regimen the lowest dosage of ethinyl estradiol commonly used today with drospirenone, an innovative progestin. Drospirenone is a compound closely resembling progesterone, but with the antimineralocorticoid and antiandrogenic properties of a related therapeutic agent, the diuretic, antihypertensive and androgen receptor antagonist, 17alpha-spironolactone. The prolongation of hormonally active pills in the monthly drospirenone/ethinyl estradiol cycle from 21 days to 24 days, followed by 4 days of inactive pills, is an interesting variant of the recently developed extended pill regimens (1). Recent contraceptive research has focused on improving side effect profiles and providing noncontraceptive health and lifestyle advantages. Many of these benefits are now supported with evidence-based medicine (2). Most available oral contraceptives improve cycle regularity, menstrual pain, excessive menstrual flow and acne. However, weight gain, bloating, food cravings, breast tenderness and mood alterations (especially irritability and depression and the complex of affective, behavioral and somatic symptoms of premenstrual syndrome [PMS] and the severe form of PMS, premenstrual dysphoric disorder [PMDD]) are not generally improved with the traditional oral contraceptive formulations (3). Drospirenone/ethinyl estradiol 24/4 is currently the only hormonally based contraceptive regimen with large, randomized, controlled trials demonstrating efficacy for PMDD. It has received U.S. Food and Drug Administration (FDA) indications not only for the prevention of pregnancy but also for PMDD and for moderate acne vulgaris in women who choose oral contraception for birth control (4, 5).

Drospirenone/ethinyl estradiol. Publishing Authors By Initials

AJ Rapkin,SN Sorger,SA Winer,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Drospirenone/ethinyl estradiol. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Drugs of today (Barcelona, Spain : 1998)

VOLUME: 44

Page Numbers: 133-45

Journal Abbreviation: Drugs Today

ISSN: 1699-3993

DAY: 4

MONTH: Feb

YEAR: 2008

Drospirenone/ethinyl estradiol. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101160518

Drospirenone/ethinyl estradiol. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Drospirenone/ethinyl estradiol. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Drospirenone/ethinyl estradiol.

AFFILIATION: Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, California, USA. arapkin@mednet.ucla.edu.

Country: Spain

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Drugs Today (Barc)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Drospirenone/ethinyl estradiol Related Publications

• A framework for interactive examination of automatic segmented tumors in a virtual environment.
• A simple approach to quality assurance in a complex ambulatory care setting.
• Advances in adjuvant endocrine therapy for postmenopausal women.
• Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
• Auditory cortex mapmaking: principles, projections, and plasticity.
• Branched projections in the auditory thalamocortical and corticocortical systems.
• Commoner skin diseases of the external genitalia.
• Concurrent tonotopic processing streams in auditory cortex.
• Connections of cat auditory cortex: I. Thalamocortical system.
• Connections of cat auditory cortex: II. Commissural system.
• Connections of cat auditory cortex: III. Corticocortical system.
• Cutaneous leishmaniasis; report of a case and summary of the newer concepts.
• Drospirenone/ethinyl estradiol.
• Elastic fibers in unusual dermatoses.
• Follow-up care of patients with breast cancer.
• Herpes zoster and malignancy.
• Heterogeneity of breast cancer and implications of adjuvant chemotherapy.
• How does infiltration behavior modify the composition of ambient PM2.5 in indoor spaces? An analysis of RIOPA data.
• Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors.
• Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.
• Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time.
• Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
• Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
• Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions.
• Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
• Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.
• Sarcoidosis mimicking metastatic breast cancer.
• The pharmacologic management of premenstrual dysphoric disorder.
• Uterine inversion associated with bicornuate uterus.
• Vascular compliance in the cardiometabolic syndrome.